

The 2017 Royal Society Of Medicine Cystic Fibrosis Symposium

Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis

Annabelle Lee, Andrew L. Jones

PII: S1526-0542(18)30070-8
DOI: https://doi.org/10.1016/j.prrv.2018.05.009
Reference: YPRRV 1265

To appear in: *Paediatric Respiratory Reviews*

Please cite this article as: A. Lee, A.L. Jones, Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis, *Paediatric Respiratory Reviews* (2018), doi: https://doi.org/10.1016/j.prrv.2018.05.009

Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis

Annabelle Lee [1], Andrew L. Jones [1].

[1]Department of Cystic Fibrosis, Royal Brompton & Harefield Foundation NHS Trust.

Corresponding author:

Dr A Lee (annabellelee@nhs.net)

Cystic Fibrosis Department

Royal Brompton Hospital

Sydney Street

Chelsea

London

SW3 6NP

Conflict of interest:

No conflicts of interest to declare

Abstract

Chronic *Pseudomonas aeruginosa* infection is associated with a decline in lung function and overall poorer prognosis in the cystic fibrosis population. Molecular typing of *Pseudomonas aeruginosa* has identified multiple clonal strains with increased virulence and transmissibility. *Pseudomonas aeruginosa* ST235 is an emerging clonal strain with multi-drug resistance and is associated with more virulent infections. Novel cephalosporins, which have recently been introduced to clinical practice, may have higher efficacy against multi-drug resistant bacteria.

Keywords: *Pseudomonas aeruginosa*, cystic fibrosis, molecular typing, ceftolozane-tazobactam